Amiloidosis cardíaca: reporte de caso

Adriana E. Viñas-Mendieta; Mario B. García-Saavedra

doi:10.47487/apcyccv.v3i2.207

Authors

Adriana E. Viñas-Mendieta Centro Médico Naval ‘’Cirujano Mayor Santiago Távara’’. Bellavista, Perú. https://orcid.org/0000-0003-1018-8695
Mario B. García-Saavedra Centro Médico Naval ‘’Cirujano Mayor Santiago Távara’’. Bellavista, Perú. https://orcid.org/0000-0002-3534-5119

DOI:

https://doi.org/10.47487/apcyccv.v3i2.207

Keywords:

Amyloidosis, Heart failure, Echocardiography

Abstract

Amyloidosis is a multisystem disease caused by infiltration of misfolded proteins; cardiac involvement determines its prognosis. There are several types of precursor proteins capable of causing the disease; however, only two affect the heart, clonal immunoglobulin light chains (AL) and tetrameric transthyretin (TTR) protein. It is an underdiagnosed disease and, in late stages, it has a poor prognosis. We present the case of an older adult patient with progressive cardiac and extracardiac manifestations, as well as laboratory and echocardiographic criteria that brought us closer to the diagnosis of cardiac amyloidosis and also allowed us to assess the prognosis. The patient had a torpid evolution with a fatal outcome. The pathological anatomy studies allowed us to confirm our diagnostic presumption.

Downloads

Download data is not yet available.

References

Moreno JMM, Ocmin JA, García SE, Aguilar C, Alarco W. Amiloidosis cardíaca: Experiencia en un Instituto Cardiovascular de referencia nacionaI. Arch Peru Cardiol Cir Cardiovasc. 2020;1(2):95-104. doi:

47487/apcyccv.v1i2.40.

Rapezzi C, Lorenzini M, Longhi S, Milandri A, Gagliardi C, Bartolomei I, et al. Cardiac amyloidosis: the great pretender. Heart Fail Rev. 2015;20(2):117-24. doi: 10.1007/s10741-015-9480-0.

Fine NM, Davis MK, Anderson K, Delgado DH, Giraldeau G, Kitchlu A, et al. Canadian Cardiovascular Society/Canadian Heart Failure Society Joint Position Statement on the Evaluation and Management of

Patients with Cardiac Amyloidosis. Can J Cardiol. 2020;36(3):322-334. doi: 10.1016/j.cjca.2019.12.034.

Witteles RM, Liedtke M. AL Amyloidosis for the Cardiologist and Oncologist: Epidemiology, Diagnosis, and Management. JACC CardioOncol. 2019;1(1):117-130. doi: 10.1016/j.jaccao.2019.08.002.

Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2021;42(16):1554-1568. doi: 10.1002/ejhf.2140.

Witteles RM, Bokhari S, Damy T, Elliott PM, Falk RH, Fine NM, et al. Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice. JACC Heart Fail. 2019;7(8):709-716. doi: 10.1016/j.

jchf.2019.04.010.

Rapezzi C, Aimo A, Serenelli M, Barison A, Vergaro G, Passino C, et al. Critical Comparison of Documents From Scientific Societies on Cardiac Amyloidosis: JACC State-of-the-Art Review. J Am Coll Cardiol. 2022;79(13):1288-1303. doi: 10.1016/j.jacc.2022.01.036..

Lee Chuy K, Drill E, Yang JC, Landau H, Hassoun H, Nahhas O, et al. Incremental Value of Global Longitudinal Strain for Predicting Survival in Patients with Advanced AL Amyloidosis. JACC

CardioOncol. 2020;2(2):223-231. doi: 10.1016/j.jaccao.2020.05.012.

Palladini G, Sachchithanantham S, Milani P, Gillmore J, Foli A, Lachmann H, et al. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood. 2015;126(5):612-5. doi: 10.1182/blood-2015-01-620302.

Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2018;379(11):1007-1016. doi: 10.1056/NEJMoa1805689.

Griffin JM, Rosenthal JL, Grodin JL, Maurer MS, Grogan M, Cheng RK. ATTR Amyloidosis: Current and Emerging Management Strategies: JACC: CardioOncology State-of-the-Art Review. JACC: CardioOncology. JACC CardioOncol. 2021;3(4):488-505. doi: 10.1016/j.jaccao.2021.06.006.